Abstract
PCN142 - Cost-Effectiveness Analysis of Oral Fentanyl Formulations for Breakthrough Cancer Pain Treatment
Highlights
PCN142 Cost-Effectiveness Analysis of Oral Fentanyl Formulations for Breakthrough Cancer Pain Treatment D’Angiolella LS1, Cortesi PA2, Kheiraoui F3, Allegri M4, Casale G5, Vellucci R6, Mantovani LG1 1University of Milan Bicocca, Monza, Italy, 2University of Milano-Bicocca, Monza, Italy, 3Catholic University of the Sacred Heart, Rome, Italy, 4University of Parma, Parma, Italy, 5ANTEA Center, Rome, Italy, 6University Hospital of Careggi, Florence, Italy Objectives: Breakthrough cancer pain (BTcP) in cancer population, reported a high prevalence and health care costs with a negative impact on quality of life and medical outcomes
The higher efficacy of FCLS related to a faster effect (15 minutes from onset) in reducing pain intensity (PI) is translates in a reduction of cost and increasing quality-adjusted life-years (QALYs) compare to the other formulation in the treatment for BTCP in Italy
In patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma (HL) after autologous stem cell transplantation (ASCT) Incremental cost-effectiveness ratio (ICER) was 86.4 thousands euro per life year (LY) for brentuximab vedotin (BV) vs Ch ± RT and 95.2 thousands euro for Ch ± RT + allogeneic stem cell transplantation (alloSCT) vs Ch ± RT
Summary
PCN142 Cost-Effectiveness Analysis of Oral Fentanyl Formulations for Breakthrough Cancer Pain Treatment D’Angiolella LS1, Cortesi PA2, Kheiraoui F3, Allegri M4, Casale G5, Vellucci R6, Mantovani LG1 1University of Milan Bicocca, Monza, Italy, 2University of Milano-Bicocca, Monza, Italy, 3Catholic University of the Sacred Heart, Rome, Italy, 4University of Parma, Parma, Italy, 5ANTEA Center, Rome, Italy, 6University Hospital of Careggi, Florence, Italy Objectives: Breakthrough cancer pain (BTcP) in cancer population, reported a high prevalence and health care costs with a negative impact on quality of life and medical outcomes. This research aims to assess the cost-effectiveness of Pazopanib compared to Sunitinib as a first-line treatment for patients with metastatic RCC (mRCC) from the perspective of Egyptian health care system. Methods: A Markov state transition model was developed to perform a cost-utility analysis to compare the cost and health benefits of Pazopanib to that of Sunitinib in treatment of mRCC; a cohort simulation approach was used.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
